Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence
- 21 June 2018
- journal article
- review article
- Published by Springer Science and Business Media LLC in Current Treatment Options in Oncology
- Vol. 19 (8), 38
- https://doi.org/10.1007/s11864-018-0555-8
Abstract
Diffuse large B cell lymphoma (DLBCL) arises from extranodal organs in about 30% of cases. Its prognosis and risk of recurrence in the central nervous system (CNS) vary according to the primary site of origin. Recent studies begin to clarify these differences using molecular classification. Testicular, breast, and uterine DLBCL (as well as possibly primary cutaneous DLBCL, leg-type) share a high prevalence of the non-germinal center B cell (non-GCB) phenotype and the MYD88/CD79B-mutated (MCD) genotype. These biologic features, which resemble primary CNS lymphoma, may underlie their stage-independent propensity for CNS involvement. Management of these lymphomas should involve CNS prophylaxis, preferably using systemic high-dose methotrexate to prevent intraparenchymal recurrence. Involvement of the kidneys, adrenal glands, ovary, bone marrow, lung, or pleura usually indicates disseminated disease, conferring worse prognosis. Involvement of these sites is often associated with high CNS-International Prognostic Index (IPI), concurrent MYC and BCL2 or BCL6 rearrangements, or intravascular lymphoma—risk factors warranting CNS prophylaxis. In contrast, craniofacial, thyroid, localized bone, or gastric lymphomas have a variable prevalence of the non-GCB phenotype and lack MYD88 mutations. Their outcomes with standard immunochemotherapy are excellent, and the risk of CNS recurrence is low. We recommend individualized consideration of CNS prophylaxis based on the CNS-IPI score and anatomical proximity in cases of epidural, orbital, or skull involvement. Rituximab-containing immunochemotherapy is a standard approach for all extranodal DLBCLs. Surgery is no longer required for any primary site, but routine consolidative radiation therapy is recommended for testicular lymphoma. Radiation therapy also appears to be associated with better progression-free survival in primary bone DLBCL. Future studies should better distinguish primary from secondary sites of extranodal involvement, and investigate the association of newly identified genotypes with the risk of CNS or systemic recurrence.Keywords
Funding Information
- American Cancer Society (128608-RSGI-15-211-01-CPHPS)
- National Institute of General Medical Sciences (U54GM115677)
This publication has 129 references indexed in Scilit:
- Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphomaLaboratory Investigation, 2014
- Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in HaematologyBritish Journal of Haematology, 2013
- Recurrent Mutations of MYD88 and TBL1XR1 in Primary Central Nervous System LymphomasClinical Cancer Research, 2012
- Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)Journal of Hematology & Oncology, 2012
- Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapseHaematologica, 2011
- Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocationsHaematologica, 2009
- Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study GroupAnnals Of Oncology, 2007
- Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'AdulteJournal of Clinical Oncology, 2005
- Primary hepatic lymphomaCancer, 2001
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000